Seminars in Oncology
Volume 33 , Pages 7-10 , February 2006

Therapeutic Advances in Cutaneous T-Cell Lymphoma (CTCL): From Retinoids to Rexinoids

  • Rudolf Stadler

      Affiliations

    • Corresponding Author InformationAddress correspondence and reprint requests to Prof Rudolf Stadler, MD, Hautklinik, Klinikum Minden, Portastr. 7-9, 32423 Minden, Germany
    • ,
  • Almut Kremer

References 

  1. Farol LT , Hymes KB . Bexarotene (A clinical review) . Expert Rev Anticancer Ther . 2004;4:180–188
  2. Zhang C , Hazarika P , Ni X , et al.   Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells (Relevance to mechanism of therapeutic action) . Clin Cancer Res . 2002;8:1234–1240
  3. Chambon P . The retinoid signaling pathway (molecular and genetic analyses) . Semin Cell Biol . 1994;5:115–125
  4. Tracey L , Villuendas R , Dotor AM , et al.   Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway (An expression profile study) . Blood . 2003;102:1042–1050
  5. Breneman D , Duvic M , Kuzel T , et al.   Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma . Arch Dermatol . 2002;138:325–332
  6. Heald P , Mehlmauer M , Martin AG , et al.   Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma (Results of the phase III clinical trial) . J Am Acad Dermatol . 2003;49:801–815
  7. Mahrle G , Thiele B . Retinoids in cutaneous T cell lymphomas . Dermatologica . 1987;175:145–150 (suppl 1)
  8. Miller VA , Benedetti FM , Rigas JR , et al.   Initial clinical trial of a selective retinoid X receptor ligand, LGD1069 . J Clin Oncol . 1997;15:790–795
  9. Rizvi NA , Marshall JL , Dahut W , et al.   A Phase I study of LGD1069 in adults with advanced cancer . Clin Cancer Res . 1999;5:1658–1664
  10. Duvic M , Martin AG , Kim Y , et al.   Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma . Arch Dermatol . 2001;137:581–593
  11. Duvic M , Hymes K , Heald P , et al.   Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma (multinational phase II-III trial results) . J Clin Oncol . 2001;19:2456–2471
  12. Querfeld C , Rosen ST , Guitart J , et al.   Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma . J Am Acad Dermatol . 2004;51:25–32
  13. McGinnis KS , Junkins-Hopkins JM , Crawford G , et al.   Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma (Clinical synergism and possible immunologic mechanisms) . J Am Acad Dermatol . 2004;50:375–379
  14. Michaelis S , Cozzio A , Kempf W , et al.   Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides . Dermatology . 2004;209:72–74
  15. Singh F , Lebwohl MG . Cutaneous T-cell lymphoma treatment using bexarotene and PUVA (A case series) . J Am Acad Dermatol . 2004;51:570–573
  16. Stadler R , Otte HG , Luger T , et al.   Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II . Blood . 1998;92:3578–3581

 This supplement was supported by an unrestricted educational grant from Zeneus Pharma Ltd.

PII: S0093-7754(05)00510-5

doi: 10.1053/j.seminoncol.2005.12.016

Seminars in Oncology
Volume 33 , Pages 7-10 , February 2006

Article Tools

* Image Usage & Resolution